No Data
No Data
No Data
No Data
No Data
MorphoSys AG Sees Shift in Major Shareholders
TipRanks12:00 ET
MorphoSys AG Unveils Cancer Drug Trial Progress
TipRanksApr 24 11:57 ET
MorphoSys AG Shares Shift in Major Holdings
TipRanksApr 24 10:57 ET
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/
MorphoSysApr 24 00:00 ET
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million.Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled rec
BenzingaApr 23 15:03 ET
Morgan Stanley Adjusts Stake in MorphoSys AG
TipRanksApr 22 11:58 ET
Jordan_Biter : Probably too late to buy now right?
TrytosaveabitOP Jordan_Biter: Depends? If the offer is true? And high enough? Some analysts are setting PT at 80? I personally don’t see that. But I can see 20/25 very possible. NFA just what I’m seeing right now! GL
Jordan_Biter : Thank you!!
TrytosaveabitOP Jordan_Biter: You’re welcome!
No Data
No Data
Jaguar8 : Grrrr
Jaguar8 : Even fake news abound in stock market
TrytosaveabitOP Jaguar8: Yup yup! It’s everywhere